Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Dihydrocodeine is an opioid analgesic agent used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis.
- Mechanism
- Curator reviewed
Dihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors.
- Primary indication
- Dihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain.Curator reviewed · 3 structured indications
- Formula / weight
- C18H23NO3 · 301.3801 g/mol (avg)
- First approval
- United States, 2006
- Code names
- IDS-ND-008(SECT.2) · NSC-231319
- Brand names
- Dvorah
- Trezix
Resolves to
RBOXVHNMENFORY-DNJOTXNNSA-NSMILES[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OCWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Dihydrocodeine, and which of those have an active Phase 3 trial?